Pneumococcal Pneumonia - Pipeline Insight, 2025

This “Pneumococcal Pneumonia - Pipeline Insight, 2025” report provides comprehensive insights about 12+ companies and 15+ pipeline drugs in Pneumococcal Pneumonia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Pneumococcal Pneumonia: Understanding

Pneumococcal Pneumonia: Overview

Pneumococcal Pneumonia disease is a name for any infection caused by bacteria called Streptococcus pneumoniae, or pneumococcus. Pneumococcal infections can range from ear and sinus infections to pneumonia and bloodstream infections. There are vaccines to help prevent pneumococcal disease. Pneumococcal pneumonia is a potentially serious disease. Pneumococcal disease is caused by bacteria that are spread by airborne droplets, or by direct contact with infected saliva or mucus. Some of these infections are considered “invasive”. Invasive pneumococcal disease (IPD) is a group of illnesses caused by pneumococcus bacteria. The common symptoms of pneumococcal pneumonia, a lung infection, includes fever and chills, cough, rapid breathing or difficulty breathing, chest pain and older adults with pneumococcal pneumonia may also experience confusion or low alertness, rather than the more common symptoms. Complications of pneumococcal pneumonia include empyema (infection around the lungs and in the chest cavity), pericarditis (inflammation of the outer lining of the heart) end bronchial obstruction (blockage of the airway that allows air into the lungs), with atelectasis (collapse within the lungs) and abscess (collection of pus) in the lungs. Pneumococcal pneumonia kills about 1 in 20 who get it.

Streptococcus pneumoniae frequently colonizes the nasopharynx and from the nasopharynx, pneumococci can spread directly via the airway to the lower respiratory tract, causing pneumonia, or to the sinuses or middle ears, causing medical morbidity. Bacteria may also penetrate the epithelial cell surface, resulting in local infection or bacteremia. The pleura and meninges can be seeded by local spread of infection or by bacteremia. Invasive pneumococcal disease (IPD) is defined as isolation of bacteria from a normally sterile site, such as blood, cerebrospinal fluid, or pleural space, and results from invasion of the respiratory epithelium. Diagnosis and treatment varies depending on the type of pneumococcal disease with which the patient is infected. When diagnosing IPD, such as meningitis or bloodstream infections, samples of cerebrospinal fluid or blood are collected and sent to a laboratory for testing. Early diagnosis and treatment are very important for IPD. When non-invasive pneumococcal disease, such as ear infections, is suspected, diagnosis is generally made by a healthcare provider after performing a physical exam.

Pneumococcal disease is treated with antibiotics. However, some pneumococcal bacteria have become resistant to certain antibiotics used to treat these infections .Antibiotic treatment for serious pneumococcal infections typically includes ‘broad-spectrum’ antibiotics until results of antibiotic sensitivity testing are available. Antibiotic sensitivity testing shows which antibiotics will be most successful at treating a bacterial infection. Broad-spectrum antibiotics work against a wide range of bacteria. Once the sensitivity of the bacteria is known, doctors may choose a more targeted (or ‘narrow-spectrum’) antibiotic. The number of antibiotic-resistant pneumococcal infections has decreased due to the success of pneumococcal conjugate vaccination. In addition to vaccination, appropriate use of antibiotics may also slow or reverse drug-resistant pneumococcal infections.ne of the best ways to help protect against certain types of infectious diseases, including pneumococcal, is through vaccination.

'Pneumococcal Pneumonia - Pipeline Insight, 2025' report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Pneumococcal Pneumonia pipeline landscape is provided which includes the disease overview and Pneumococcal Pneumonia treatment guidelines. The assessment part of the report embraces, in depth Pneumococcal Pneumonia commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pneumococcal Pneumonia collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Pneumococcal Pneumonia R&D. The therapies under development are focused on novel approaches to treat/improve Pneumococcal Pneumonia.

Pneumococcal Pneumonia Emerging Drugs Chapters

This segment of the Pneumococcal Pneumonia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Pneumococcal Pneumonia Emerging Drugs

Trimodulin : Biotest AG

Trimodulin (BT588, predecessor BT086) is a human plasma-derived native polyvalent antibody preparation for intravenous administration. Trimodulin contains immunoglobulins IgM (~23%), IgA (~ 21%) and IgG (~56%). Trimodulin mediates its mode of action via three potential mechanisms which are; opsonization of causal pathogens, neutralizing of microbial pathogens and their virulence factors (endo- and exotoxins) and targeting the host inflammatory response (anti-inflammatory properties). Currently, trimodulin is under clinical development for severe community-acquired pneumonia (sCAP). These patients suffer from very severe lung infections, and a high number need life saving measures such as mechanical ventilation. Currently, the drug is in Phase III stage of its development for the treatment of Pneumococcal Pneumonia.

VAX-24: Vaxcyte, Inc.

VAX-24 is a clinical-stage 24-valent pneumococcal conjugate vaccine (PCV) designed to improve upon existing vaccines by covering the serotypes responsible for most of the remaining pneumococcal disease currently in circulation, while maintaining an immunogenicity profile comparable to PCVs available today. In October 2022, the company announced positive topline results from the VAX-24 Phase I/II proof-of-concept study in adults aged 18 to 64 the findings indicate a potential best-in-class profile for VAX-24 and validate our carrier-sparing approach to enable the development of broader-spectrum PCVs. VAX-24 has been granted FDA Breakthrough Therapy designation for the prevention of invasive pneumococcal disease in adults. Currently, the drug is in Phase II stage of its development for the treatment of Pneumococcal Pneumonia.

Pneumococcal Pneumonia: Therapeutic Assessment

This segment of the report provides insights about the different Pneumococcal Pneumonia drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Pneumococcal Pneumonia

• There are approx. 12+ key companies which are developing the therapies for Pneumococcal Pneumonia. The companies which have their Pneumococcal Pneumonia drug candidates in the most advanced stage, i.e. phase III include, Biotest AG

Phases

The report covers around 15+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Pneumococcal Pneumonia pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Pneumococcal Pneumonia: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Pneumococcal Pneumonia therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Pneumococcal Pneumonia drugs.

Pneumococcal Pneumonia Report Insights

• Pneumococcal Pneumonia Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Pneumococcal Pneumonia Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Pneumococcal Pneumonia drugs?
• How many Pneumococcal Pneumonia drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Pneumococcal Pneumonia?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Pneumococcal Pneumonia therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Pneumococcal Pneumonia and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Biotest AG
• Vaxcyte, Inc.

Eubiologics Ltd.

Eagle Pharmaceuticals

• GlaxoSmithKline

Key Products

• Trimodulin
• VAX-24
• EuPVC
• CAL02
• AFX3772

This product will be delivered within 2 business days.